Remove 2030 Remove Communication Remove Pharmaceutical Companies
article thumbnail

Navigating tariffs and diplomacy: the future of India-US pharmaceutical trade

Pharmaceutical Technology

Leyla Hasanzadeh June 18, 2025 Share Copy Link Share on X Share on Linkedin Share on Facebook Tech transfer for manufacturing purposes in India will be difficult if Trump imposes import duties on pharmaceuticals. The goal is to take annual bilateral trade between the two nations to $500 billion by 2030 from the current $190 billion.

article thumbnail

Beyond the Brand Team: Why Every Employee Needs to Be Part of the Journey

Pharmaceutical Commerce

Jacqueline Durett Few times in the evolution of a pharmaceutical company are as exciting as during the flurry of launch readiness activities focused on bringing a new drug to market. 1 One often overlooked major reason many drug launches underperform comes down to communications. The key is to start early. References 1.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

The impact of climate change on the pharma supply chain

Pharmaceutical Technology

Pharmaceutical companies need to be prepared to answer the call for increased demand and supply into new markets, ensuring the proper resources and logistics framework are in place. In addition, a paper published in 2019, concluded that the pharmaceutical industry produced 48.55

article thumbnail

Sustainability: Corporate Ambition, Governance, & Accelerated Delivery

ISPE

Transforming Our World: The 2030 Agenda for Sustainable Development.” A collaborative mindset must prevail between pharmaceutical companies, suppliers, and regulators and include strategic partnerships that go beyond the pharmaceutical sector so we can move together to a more sustainable future. 1 United Nations.

article thumbnail

Sandoz targets barriers to biosimilar accessibility with latest initiative

Pharmaceutical Technology

Generic and biosimilar pharmaceutical company and Novartis subsidiary Sandoz announced its plan to accelerate patient access to biosimilars. In a 15 June statement, Sandoz said that it hoped the Act4Biosimilars action plan will provide actionable solutions to overcome barriers preventing patient access to biosimilars.

article thumbnail

The EU joint HTA procedure: a gate or barrier for access?

Pharmaceutical Technology

By 2030, JCAs will be carried out on all medicinal products with an EMA-issued MA. Visit our privacy policy for more information about our services, how we may use, process and share your personal data, including information on your rights in respect of your personal data and how you can unsubscribe from future marketing communications.

article thumbnail

The rise and rise of ESG in the pharmaceutical sector – is a zero-waste supply?chain possible?? 

Pharmaceutical Technology

AstraZeneca has announced its supply chain will be carbon negative by 2030. Of the world’s 20 largest pharmaceutical companies, 17 have launched programmes tailored towards increasing medication access in low- and middle-income countries – up from just eight in 2010. A similar theme is evident in company filings.